Significance of p53 immunostaining in mesothelial proliferations and correlation with TP53 mutation status
暂无分享,去创建一个
[1] A. Churg,et al. CD146 immunohistochemical staining for the separation of benign from malignant mesothelial proliferations , 2021, Virchows Archiv.
[2] A. Churg,et al. The Separation of Benign and Malignant Mesothelial Proliferations , 2020, The American journal of surgical pathology.
[3] L. Chirieac,et al. Molecular characterization of diffuse malignant peritoneal mesothelioma , 2020, Modern Pathology.
[4] M. Balancin,et al. Mutational Profiling of Driver Tumor Suppressor and Oncogenic Genes in Brazilian Malignant Pleural Mesotheliomas , 2020, Pathobiology.
[5] D. Huntsman,et al. Major p53 immunohistochemical patterns in in situ and invasive squamous cell carcinomas of the vulva and correlation with TP53 mutation status , 2020, Modern Pathology.
[6] S. Imbeaud,et al. Genetic alterations of malignant pleural mesothelioma: association with tumor heterogeneity and overall survival , 2020, Molecular oncology.
[7] R. Schmid,et al. Biomarker-guided targeted and immunotherapies in malignant pleural mesothelioma , 2020, Therapeutic advances in medical oncology.
[8] F. Cappuzzo,et al. Mutational Profile of Malignant Pleural Mesothelioma (MPM) in the Phase II RAMES Study , 2019, Cancers.
[9] S. Ganesan,et al. Genomic characterization of malignant pleural mesothelioma and associated clinical outcomes. , 2018, Cancer treatment and research communications.
[10] A. Churg,et al. Use of Programmed Death Ligand-1 (PD-L1) Staining to Separate Sarcomatoid Malignant Mesotheliomas From Benign Mesothelial Reactions. , 2020, Archives of pathology & laboratory medicine.
[11] M. Köbel,et al. p53 immunohistochemistry is an accurate surrogate for TP53 mutational analysis in endometrial carcinoma biopsies , 2019, The Journal of pathology.
[12] M. Köbel,et al. Interpretation of P53 Immunohistochemistry in Endometrial Carcinomas: Toward Increased Reproducibility , 2018, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.
[13] David L. Gibbs,et al. Integrative Molecular Characterization of Malignant Pleural Mesothelioma. , 2018, Cancer discovery.
[14] Chunlei Liu,et al. ClinVar: improving access to variant interpretations and supporting evidence , 2017, Nucleic Acids Res..
[15] N. Rosenfeld,et al. Optimized p53 immunohistochemistry is an accurate predictor of TP53 mutation in ovarian carcinoma , 2016, The journal of pathology. Clinical research.
[16] S. Leung,et al. An Immunohistochemical Algorithm for Ovarian Carcinoma Typing , 2016, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.
[17] Thomas D. Wu,et al. Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations , 2016, Nature Genetics.
[18] K. Schmid,et al. Mdm2 protein expression is strongly associated with survival in malignant pleural mesothelioma. , 2014, Future oncology.
[19] F. Galateau-Sallé,et al. The Separation of Benign and Malignant Mesothelial Proliferations , 2000, Archives of pathology & laboratory medicine.
[20] A. Reuss,et al. The biological and clinical value of p53 expression in pelvic high‐grade serous carcinomas , 2010, The Journal of pathology.
[21] Claire W Michael,et al. The use of immunohistochemistry to distinguish reactive mesothelial cells from malignant mesothelioma in cytologic effusions , 2010, Cancer cytopathology.
[22] P. Hasleton,et al. Sensitivity and specificity of immunohistochemical antibodies used to distinguish between benign and malignant pleural disease: a systematic review of published reports , 2006, Histopathology.
[23] R. Attanoos,et al. The use of immunohistochemistry in distinguishing reactive from neoplastic mesothelium. A novel use for desmin and comparative evaluation with epithelial membrane antigen, p53, platelet‐derived growth factor‐receptor, P‐glycoprotein and Bcl‐2 , 2003, Histopathology.
[24] I. Downie,et al. Immunohistochemical analysis still has a limited role in the diagnosis of malignant mesothelioma. A study of thirteen antibodies. , 2001, American journal of clinical pathology.
[25] A. Nicholson,et al. The use of histological and immunohistochemical markers to distinguish pleural malignant mesothelioma and in situ mesothelioma from reactive mesothelial hyperplasia and reactive pleural fibrosis , 1999, The Journal of pathology.
[26] V. Roggli,et al. The diagnosis of desmoplastic malignant mesothelioma and its distinction from fibrous pleurisy: a histologic and immunohistochemical analysis of 31 cases including p53 immunostaining. , 1998, American journal of clinical pathology.
[27] A. Giordano,et al. p53 immunostaining in differential diagnosis of pleural mesothelial proliferations. , 1997, Anticancer research.
[28] P. Cagle,et al. p53 immunostaining in the differentiation of reactive processes from malignancy in pleural biopsy specimens. , 1994, Human pathology.
[29] A. Gibbs,et al. p53 immunostaining in the distinction between benign and malignant mesothelial proliferations using formalin‐fixed paraffin sections , 1992, The Journal of pathology.
[30] E. van Marck,et al. Immunoreactivity for p53 protein in malignant mesothelioma and non‐neoplastic mesothelium , 1992, The Journal of pathology.
[31] N. Shepherd,et al. p53 expression is common in malignant mesothelioma , 1992, Histopathology.